Andrographolide Exerts Chondroprotective Activity in Equine Cartilage Explant and Suppresses Interleukin-1[beta]-Induced MMP-2 Expression in Equine Chondrocyte Culture

• Published in: International scholarly research notices Vol. 2014
• Main Authors: Tangyuenyong, Siriwan, Viriyakhasem, Nawarat, Peansukmanee, Siriporn, Kongtawelert, Prachya, Ongchai, Siriwan
• Format: Journal Article
• Language: English
• Published: New York Hindawi Limited 01.01.2014
• Subjects: Collagen; Cytokines; Donations; Enzymes; Horses; Rheumatoid arthritis; Stem cells; Studies; Tissue engineering; Veterinary medicine
• ISSN: 2356-7872
• DOI: 10.1155/2014/464136

Cartilage erosion in degenerative joint diseases leads to lameness in affected horses. It has been reported that andrographolide from Andrographis paniculata inhibited cartilage matrix-degrading enzymes. This study aimed to explore whether this compound protects equine cartilage degradation in the explant culture model and to determine its effect on matrix metalloproteinase-2 (MMP-2) expression, a matrix-degrading enzyme, in equine chondrocyte culture. Equine articular cartilage explant culture was induced by 25 ng/mL interleukin-1β, a key inducer of cartilage degeneration, in cultures with or without andrographolide ranging from 10 to 50 μM. After 3-21 days, they were analyzed for the markers of cartilage degradation. It was found that interleukin-1β increased the release of sulfated glycosaminoglycans and hyaluronan from the explants into the culture media consistently with the decrease in uronic acid and collagen content in the cartilage explants. These catabolic effects were inhibited when cotreated with interleukin-1β and andrographolide. In primary equine chondrocytes, andrographolide suppressed interleukin-1β-induced MMP-2 mRNA expression and MMP-2 activity in the culture medium. These results confirmed the in vitro potent chondroprotective activities of this compound which were performed in cartilage explants and on a cellular level. These may indicate the application of andrographolide for therapeutic use in equine degenerative joint diseases.